Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume – Still a Buy?

Shares of Pharvaris N.V. (NASDAQ:PHVS) saw an uptick in trading volume on Tuesday . Approximately 611,090 shares changed hands during mid-day trading, an increase of 140% from the previous session’s volume of 254,849 shares.The stock last traded at $35.3840 and had previously closed at $34.71.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PHVS. Wolfe Research initiated coverage on shares of Pharvaris in a research report on Thursday, April 9th. They set an “outperform” rating and a $42.00 target price on the stock. Wall Street Zen upgraded shares of Pharvaris from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. UBS Group set a $74.00 price objective on shares of Pharvaris in a report on Wednesday, May 13th. Royal Bank Of Canada cut their price objective on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research report on Monday, April 6th. Finally, Morgan Stanley increased their target price on shares of Pharvaris from $41.00 to $46.00 and gave the company an “overweight” rating in a research note on Thursday, June 25th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Pharvaris presently has an average rating of “Moderate Buy” and an average target price of $49.64.

Pharvaris Stock Up 1.2%

The business has a 50-day moving average price of $30.68 and a 200-day moving average price of $28.07. The firm has a market capitalization of $2.30 billion, a P/E ratio of -11.10 and a beta of -2.35.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.12. As a group, sell-side analysts forecast that Pharvaris N.V. will post -3.22 EPS for the current year.

Insider Activity at Pharvaris

In other Pharvaris news, Director Johannes Gerardus Chri Schikan sold 29,070 shares of the firm’s stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $30.32, for a total transaction of $881,402.40. Following the completion of the transaction, the director owned 355,167 shares in the company, valued at $10,768,663.44. This trade represents a 7.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Anne Lesage sold 21,700 shares of Pharvaris stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $30.26, for a total value of $656,642.00. Following the sale, the insider directly owned 56,450 shares in the company, valued at $1,708,177. The trade was a 27.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 215,209 shares of company stock worth $6,431,945 in the last ninety days.

Institutional Trading of Pharvaris

Several institutional investors have recently bought and sold shares of the stock. Seven Fleet Capital Management LP grew its position in Pharvaris by 472.3% in the first quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company’s stock valued at $8,947,000 after acquiring an additional 261,355 shares during the period. DV Trading LLC bought a new position in shares of Pharvaris during the first quarter valued at $4,067,000. Stempoint Capital LP lifted its holdings in shares of Pharvaris by 48.4% during the first quarter. Stempoint Capital LP now owns 86,637 shares of the company’s stock valued at $2,447,000 after acquiring an additional 28,248 shares during the period. ADAR1 Capital Management LLC boosted its stake in shares of Pharvaris by 23.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 105,528 shares of the company’s stock valued at $2,981,000 after purchasing an additional 20,000 shares in the last quarter. Finally, Amundi boosted its stake in shares of Pharvaris by 12.0% in the 1st quarter. Amundi now owns 30,952 shares of the company’s stock valued at $874,000 after purchasing an additional 3,312 shares in the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.